Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Cytokine and chemokine antibodies neutralize soluble mediators or block their receptors in immunology research. Adalimumab, infliximab and golimumab bind tumor necrosis factor alpha (TNF-α), and tocilizumab blocks the interleukin-6 (IL-6) receptor. Secukinumab and ixekizumab neutralize IL-17A, while ustekinumab, guselkumab and risankizumab act on the IL-12 and IL-23 axis. Dupilumab binds IL-4 receptor alpha, tralokinumab and lebrikizumab neutralize IL-13, and mepolizumab and benralizumab act on the IL-5 pathway. Further antibodies target IL-1β, thymic stromal lymphopoietin (TSLP) and chemokine receptors such as CCR4, which mogamulizumab binds.
Synonyms: ZTS-00008183
Riltovetbart is a canine-derived monoclonal antibody of the IgG2 κ class, specifically targeting interleukin-13 (IL13) in the Canlupfam species. This antibody is engineered for high specificity and affinity, making it an ideal tool for detailed studies of IL13's role in immune responses and potential therapeutic interventions in related canine disorders.
Synonyms: Avakine; CT-P13
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody engineered to specifically target and bind to tumor necrosis factor-alpha (TNF-α). By binding to TNF-α, Infliximab inhibits its interaction with its receptors, TNFR1 and TNFR2, effectively modulating the inflammatory response. This antibody is widely utilized in the study of autoimmune and chronic inflammatory diseases, as well as in research focused on diabetic neuropathy. Infliximab serves as a critical tool in elucidating the pathophysiological mechanisms underlying these conditions and in the development of therapeutic strategies.
Synonyms: NIS-793
Nisevokitug (NIS-793) is a recombinant human IgG2λ monoclonal antibody specifically designed to target and neutralize transforming growth factor-beta (TGF-β), encompassing both TGFB1 and TGFB2 isoforms. This antibody is produced in CHO-K1 cells, ensuring high fidelity and consistency in performance. Nisevokitug is utilized primarily in research focused on the modulation of TGF-β activity, which is crucial in various physiological and pathological processes including cell growth, inflammation, and fibrosis.
Synonyms: NNC 0109-0012
Fletikumab (NNC0109-0012) is a monoclonal antibody specifically designed to target interleukin-20 (IL-20). This antibody is utilized primarily in the study of inflammatory processes, with a focus on conditions such as rheumatoid arthritis. Fletikumab serves as a valuable tool in elucidating the role of IL-20 in inflammatory pathways and may contribute to the development of therapeutic strategies for managing rheumatoid arthritis and related inflammatory disorders.
Synonyms: ABT-122
Remtolumab (ABT-122) is a dual-variable domain immunoglobulin specifically engineered to neutralize tumor necrosis factor α (TNFα) and interleukin-17A (IL-17A). This biologic exhibits potent dual inhibition, effectively targeting both cytokines implicated in inflammatory processes. It is particularly useful in research focused on rheumatoid arthritis (RA), providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions for this condition.
BI-1808 is a human IgG1 monoclonal antibody designed to selectively target TNFR2 (Tumor Necrosis Factor Receptor 2). It functions by inhibiting the interaction between TNFR2 and its ligand TNF-α. This antibody facilitates the FcγR-dependent depletion of regulatory T cells (Tregs) and promotes the expansion of CD8+ T cells within the tumor microenvironment. BI-1808 is utilized in research focused on modulating immune responses and studying the mechanisms of immune evasion in cancer.
Synonyms: LY3074828
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody specifically designed to target the p19 subunit of interleukin 23 (IL-23). This antibody demonstrates high affinity binding to IL-23 in both human and monkey models, with dissociation constants (Kd) of 21 pM and 55 pM, respectively. By selectively inhibiting the interaction between IL-23 and its receptor IL-23R, Mirikizumab effectively modulates the immune response. This mechanism of action suggests its utility in exploring therapeutic avenues for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease in research settings.
Synonyms: CNTO-328
Siltuximab is a monoclonal antibody that targets interleukin-6 (IL-6), demonstrating significant antitumor activity. This antibody is utilized in the study of Multicentric Castleman's Disease (MCD) and is also applicable in research related to COVID-19, providing a valuable tool for investigating the role of IL-6 in these disease processes.
Telikibart is a human monoclonal antibody of the IgG1κ isotype, specifically designed to target the IL4 receptor (IL4R). For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control. This antibody is pivotal in studies investigating the role of the IL4R in immune response and inflammatory processes.
Synonyms: Anti-Human IL17A/IL-17F Recombinant Antibody
Bimekizumab is a humanized monoclonal antibody designed to selectively neutralize interleukin-17A (IL-17A) and interleukin-17F (IL-17F). These cytokines are known to promote osteogenic differentiation in human periosteum-derived cells (hPDCs). By targeting IL-17A and IL-17F, Bimekizumab effectively inhibits the inflammation-driven osteogenic differentiation, making it a valuable tool in research focused on inflammatory processes and bone metabolism.
Synonyms: SAR441344; INX-021
Frexalimab (SAR441344) is a second-generation monoclonal antibody designed to target the CD40 ligand (CD40L). This antibody demonstrates a favorable safety profile and functions by inhibiting the interaction between CD40 and CD40L, thereby modulating the immune response. Frexalimab shows potential in preventing β-cell destruction, suggesting its utility in therapeutic research related to autoimmune diseases such as multiple sclerosis, lupus erythematosus, Sjögren’s syndrome, and type I diabetes.
Synonyms: BION-1301
Zigakibart (BION-1301) is a humanized IgG4-kappa monoclonal antibody targeting TNFSF13, also known as tumor necrosis factor superfamily member 13, APRIL, or CD256. This antibody exhibits anti-inflammatory properties, making it a valuable tool for research into inflammatory processes and potential therapeutic interventions.
Synonyms: CNTO 607
Anti-IL-13 Antibody (CNTO 607) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target interleukin-13 (IL-13). This antibody is composed of a human IgG1 heavy chain and a human lambda light chain, with an approximate molecular weight of 145 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended. Anti-IL-13 Antibody (CNTO 607) is essential for research focused on the role of IL-13 in various biological processes and disease states, including allergic responses and other inflammatory conditions.
Synonyms: AIN457
Secukinumab (AIN457) is a human monoclonal antibody with high affinity for interleukin-17A (IL-17A), representing the first-in-class anti-IL-17 agent. It is utilized in research focused on inflammatory diseases including plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis. This specificity to IL-17A makes it a critical tool in the study of immune response mechanisms and therapeutic intervention in these conditions.
Synonyms: M1295
Anti-IL-13 (M1295) is a humanized monoclonal antibody specifically targeting interleukin-13 (IL-13). This antibody binds with high affinity to IL-13, a key cytokine involved in inflammatory responses, making it an essential tool for research in immunology and inflammation. Anti-IL-13 (M1295) is suitable for a variety of applications, including flow cytometry, western blotting, and immunohistochemistry, providing valuable insights into the role of IL-13 in disease processes such as asthma and allergies.
Inolimomab is a monoclonal antibody targeting the α chain of the interleukin-2 receptor (IL-2R). This antibody has shown potential in early-stage research for enhancing survival rates in patients with acute graft-versus-host disease (aGVHD). Its mechanism involves the specific inhibition of IL-2R, a critical regulator in the activation and proliferation of T lymphocytes, which play a significant role in the pathogenesis of aGVHD.
Synonyms: SRF-114
CHS-114 (SRF-114) is a fully human IgG1 monoclonal antibody designed to specifically target CCR8. This antibody has demonstrated potential utility in research focused on head and neck squamous cell carcinoma (HNSCC). For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control.
Donzakimig is a monoclonal antibody designed to target and inhibit the activity of interleukin 13 (IL-13), interleukin 22 (IL-22), and albumin (ALB). This antibody is engineered for high specificity and affinity, making it an ideal tool for research into the biological roles and interaction mechanisms of these cytokines and proteins. Donzakimig is suitable for use in various immunological assays to explore the pathophysiological implications of IL-13, IL-22, and ALB in disease states, providing valuable insights for therapeutic development.
Synonyms: ATM-001
Atrosimab (ATM-001) is an engineered Fv-Fc1κ fusion protein that exhibits high-affinity binding to human TNF receptor 1 (TNFR1), demonstrated by an EC50 of 0.37 nM. This biologic effectively inhibits TNF-induced activation of TNFR1, highlighting its utility in the investigation of chronic inflammatory diseases. Atrosimab represents a valuable tool for researchers studying the molecular pathways involved in inflammation and immune response.
Synonyms: BMS-986004
Letolizumab (BMS-986004) is a monoclonal antibody engineered to specifically target CD40L. This antibody variant is designed as a mutant IgG1 isotype that lacks effector functions, notably Fc receptor binding and complement fixation capabilities. The primary therapeutic action of Letolizumab is to mitigate rejection and thromboembolism, effectively extending survival time in clinical settings. This makes it particularly valuable in research focused on immune response modulation and transplantation immunology.
Synonyms: RG 7624; RO 5553110; NI-1401
Afasevikumab, also known as RG 7624, RO 5553110, and NI-1401, is a fully human monoclonal IgG1κ antibody designed to neutralize interleukin-17A (IL-17A) and interleukin-17F (IL-17F). This antibody exhibits potent anti-inflammatory properties by targeting and inhibiting the activity of these cytokines, which are crucial mediators in the pathogenesis of various inflammatory and autoimmune disorders. Afasevikumab is primarily utilized in research focused on the therapeutic potential in treating conditions characterized by excessive or aberrant IL-17 activity.
The Anti-TSLP Antibody is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets thymic stromal lymphopoietin (TSLP), an important cytokine involved in the initiation of allergic inflammation and immune response. This antibody is composed of the human IgG1 heavy chain and the human kappa light chain, with an estimated molecular weight of 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is ideal for research applications focusing on the role of TSLP in immune regulation and allergic diseases.
Synonyms: ABT-874
Briakinumab (ABT-874) is a fully human monoclonal antibody that specifically targets and neutralizes the p40 subunit shared by the cytokines IL-12 and IL-23. This antibody's action inhibits the signaling pathways of both interleukin-12 (IL-12) and interleukin-23 (IL-23), which are crucial mediators in the inflammatory processes associated with autoimmune disorders. Briakinumab is utilized extensively in research focused on autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, providing valuable insights into the pathophysiology of these conditions and potential therapeutic approaches.
